ritobegron (KUC 7483) / Boehringer Ingelheim - LARVOL DELTA

Vibegron shows high selectivity and potent agonist activity for β3-adrenoceptors, irrespective of receptor density. (PubMed, PLoS One) - "Clinical proof-of-concept data have been obtained for the β3-AR agonists vibegron, mirabegron, solabegron, and ritobegron; however, the selectivities of these agents have not been compared directly under the same experimental conditions. Vibegron has high β3-AR selectivity and exhibits full agonist activity, regardless of the β3-AR density. These results suggest that vibegron is a highly effective and safe drug for treating OAB."

Journal • Overactive Bladder

Drugs Currently Undergoing Preclinical or Clinical Trials for the Treatment of Overactive Bladder: A Review. (PubMed, Curr Ther Res Clin Exp) - "These are drugs acting on the autonomic nerve supply to the detrusor muscle of the urinary bladder that include the anticholinergics tarafenacin and afacifenacin and the β adrenoceptor agonists solabegron and ritobegron; drugs acting on ion channels in the detrusor muscle (eg, potassium channel openers and calcium channel blockers), drugs acting on cellular enzymes like phosphodiesterase-5 inhibitors and Rho kinase inhibitors, and drugs acting on miscellaneous targets (eg, pregabalin and trimetazidine). (Curr Ther Res Clin Exp. 2022; 83:XXX-XXX)."

Journal • Preclinical • Review • Overactive Bladder